IL-17 inhibitors may have a faster time to meaningful plaque psoriasis improvement due to the target IL-17 cytokine being more downstream in the pathway than IL-23 or TNF-α (targets of IL-23 and TNF-α inhibitors). The gene discussed is TNF; the disease is psoriasis vulgaris.